摘要
目的 了解文拉法辛缓释剂与坦度螺酮治疗广泛性焦虑障碍的疗效和安全性.方法 将符合入组标准的70例患者随机分为研究组37例和对照组33例,研究组口服文拉法辛缓释剂,对照组口服坦度螺酮,疗程4周.临床疗效判定依据汉密尔顿焦虑量表（HAMA）减分率,不良反应采用不良反应量表（TESS）评定.结果 研究组有效率75.67%,对照组有效率为78.78%,两组有效率无统计学差异（χ2=0.10,P＞0.05）.但在第2周时研究组抗焦虑效果研究组好于对照组（t=10.21,P＜0.01）,不良反应两组之间无统计学差异.结论 文拉法辛缓释剂和坦度螺酮治疗广泛性焦虑症均有较好的疗效,不良反应少.在患者经济情况容许的情况下,可首先考虑选用文拉法辛缓释剂治疗.
Objective To assess the efficacy and safety of venlafaxine extended release and tandospirone in the treatment of generalized anxiety disorder（GAD）. Methods The patients who met the inclusion criteria were recruited and divided into study group and control group. The patients in the study group were administered with venlafaxine extended release , and control group with tandospirone for 4 weeks. Clinical efficacy was evaluated using the reducing score rate of Hamilton Anxiety Scale（HA- MA）, and adverse reactions was assessed using treatment emergent symptom scale （TESS）. Results The effective rate was 75.67% and 78.78% in study group and control group respectively in the first week. There was no statistical difference in the effective rate between the two groups （ X2 = 0.10, P 〉 0.05）. At the second week, the anxiolytic effect in study group were better than that in the control group （t = 10.21, P 〈 0.01）, but there was no statistical difference in adverse reactions between the two groups. Conclusions The efficacy is equivalent between venlafaxine extended release and tandospirone on the treatment of GAD, and the adverse effects are mild. Under the accepted economic condition, venlafaxine extended release should be preferentially considered.
出处
《神经疾病与精神卫生》
2011年第1期34-36,共3页
Journal of Neuroscience and Mental Health
关键词
文拉法辛缓释剂
坦度螺酮
广泛性焦虑障碍
Venlafaxine extended release
Tandospirone
Generalized anxiety disorder
